Three Magnolias Financial Advisors LLC Makes New Investment in Danaher Corporation $DHR

Three Magnolias Financial Advisors LLC bought a new position in shares of Danaher Corporation (NYSE:DHR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,237 shares of the conglomerate’s stock, valued at approximately $939,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Veery Capital LLC lifted its stake in shares of Danaher by 3.1% in the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after purchasing an additional 48 shares during the period. Studio Investment Management LLC grew its stake in shares of Danaher by 3.3% during the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after purchasing an additional 51 shares during the period. JDH Wealth Management LLC grew its stake in shares of Danaher by 4.5% during the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after purchasing an additional 55 shares during the period. OLD Second National Bank of Aurora increased its holdings in Danaher by 0.5% in the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after purchasing an additional 57 shares during the last quarter. Finally, Adelphi Trust Co increased its holdings in Danaher by 2.5% in the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock valued at $524,000 after purchasing an additional 57 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on DHR shares. Stifel Nicolaus cut their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. The Goldman Sachs Group boosted their target price on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Wells Fargo & Company lowered their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. Finally, Barclays increased their price target on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $235.41.

Danaher Trading Up 0.9%

Shares of NYSE DHR traded up $1.94 during midday trading on Wednesday, reaching $224.78. 2,001,034 shares of the stock were exchanged, compared to its average volume of 4,449,140. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a market capitalization of $158.02 billion, a price-to-earnings ratio of 39.91, a P/E/G ratio of 2.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The business has a 50-day simple moving average of $212.41 and a two-hundred day simple moving average of $195.13.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter in the prior year, the company earned $0.77 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, equities research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.